CN

CN

News

Company News Industry News

Company News

Shining at ASCO 2026 | MediLink Therapeutics Presents Multiple Clinical Studies, Showcasing ADC Innovation

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will take place May 29 – June 2 in Chicago, IL. As the world’s largest, most influential, and authoritative oncology conference, ASCO drives global progress in cancer research, clinical development, and patient care.

2026-05-20

MediLink Therapeutics Presents Two Innovative ADC Programs at AACR 2026

MediLink Therapeutics, a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), is pleased to share two cutting-edge research posters at the AACR 2026 Annual Meeting (April 17–22, San Diego, USA).

2026-04-23

MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche

Suzhou, China, January 9th, 2026 – MediLink Therapeutics (“MediLink”) today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and commercialization of YL201, an investigational novel antibody-drug conjugate (ADC) asset targeting B7H3 across numerous solid tumor types.

2026-01-09

MediLink Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of YL217

July 2, 2025 – MediLink Therapeutics, a clinical-stage biotechnology company, today announced that the first patient has been enrolled and dosed in China in the Global Phase I clinical trial of YL217. YL217 is a CDH17-targeting antibody-drug conjugate (ADC) based on MediLink’s proprietary TMALIN® technology platform.

2025-07-03Learn more

Expanded Access Policy

MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) is a biopharmaceutical company focusing on the development of innovative medicines and bringing new therapies for patients with cancer. We conduct clinical trials to evaluate the safety and efficacy of investigational product candidates. Clinical trials are controlled research studies in humans designed to determine if an investigational product candidate is safe and effective. MediLink encourages awareness of and participation in our clinical trials. For information regarding MediLink-sponsored clinical trials, please visit clinicaltrials.gov

2025-07-02Learn more

MediLinks Appoints Dr. Weichang Zhou as Chief Technology Officer

July 1, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, is pleased to announce the appointment of Dr. Weichang Zhou as Chief Technology Officer (CTO). Leveraging his extensive industry experience in the biopharmaceutical field, Dr. Zhou will accelerate the globalization process of MediLink’s innovative pipeline.

2025-07-01Learn more

MediLink Announces YL201 Granted Breakthrough Therapy Designation by FDA

June 23, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to YL201 for the treatment of small cell lung cancer (SCLC). YL201 is an investigational B7H3-targeted antibody drug conjugate (ADC) developed based on MediLink’s proprietary TMALIN® (Tumor Microenvironment Activable LINker) technology platform.

2025-06-24Learn more

MediLink Therapeutics to Present Preclinical Data for Latest Innovations at AACR 2025

March 25, 2025- MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, announces the presentation of preclinical data for two innovative ADC programs (YL217, a CDH17-targeting ADC, and YL242, a VEGF-targeting ADC) and its next-generation dual payload platform at the upcoming AACR Annual Meeting 2025. AACR will be held in Chicago, US April 25-30.

2025-03-26Learn more

MediLink’s YL217 received FDA Clearance of IND Application

February 1, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for YL217, an investigational antibody-drug conjugate (ADC) developed by MediLink. YL217 is the 11th ADC candidate entering into clinical stage developed based on MediLink’s proprietary TMALIN® technology platform.

2025-02-02Learn more
1 2 3 4 5 6